Comparative Pharmacology
Head-to-head clinical analysis: METASTRON versus XENON XE 133 V S S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METASTRON versus XENON XE 133 V S S.
METASTRON vs XENON XE 133-V.S.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Strontium-89 chloride is a bone-seeking radiopharmaceutical that emits beta radiation. After intravenous administration, it is taken up preferentially by osteoblastic bone metastases, where its beta decay causes DNA damage and cell death in tumor cells.
Xenon Xe-133 is a radioactive gas that emits beta and gamma radiation. It distributes to the lungs and is used for ventilation-perfusion imaging. Its mechanism is based on regional distribution in the lungs, reflecting ventilation. It does not have pharmacological activity.
Metastron (strontium-89 chloride) is administered intravenously at a dose of 148 MBq (4 mCi) as a single injection.
5-10 mCi (185-370 MBq) inhaled as a single dose for pulmonary ventilation imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 50.5 days (range 20-87 days). Clinical context: due to prolonged retention in bone metastases, radiobiological half-life exceeds physical half-life; therapeutic effect persists for weeks despite declining plasma levels.
Terminal elimination half-life of approximately 3.5 minutes, corresponding to rapid washout from lungs following cessation of inhalation.
Renal excretion of strontium-89; approximately 70% excreted in urine within 48 hours, with the remainder eliminated over weeks via both renal and fecal routes (12-20% fecal).
Eliminated almost entirely via exhalation through the lungs (>95%); negligible renal or biliary/fecal excretion.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical